Psilocybin, a naturally occurring hallucinogen, shows promise in treating depression, with studies indicating a 60% reduction in symptoms among participants. In trials involving 200 individuals, nearly 70% reported significant improvements after just two doses. This aligns with findings on lysergic acid diethylamide (LSD) and mescaline, suggesting psychedelics may influence neurotransmitter receptors that affect behavior. These insights open new avenues in pharmacology and psychology, emphasizing the potential of psychedelics as transformative medicine in mental health treatment and forensic toxicology applications.
Ketamine (80 mg/kg) produced anxiogenic effects in male rats two and seven days after administration in the elevated T-maze test, while both 40 and 80 mg/kg doses decreased panic-like behavior. In the light/dark test, ketamine was anxiogenic. Isoflurane did not alter behavior in the elevated T-maze but reduced exploration of the open field center after seven days. Neither anesthetic caused oxidative liver damage. Ketamine reduced cellular metabolism and led to neuronal death in amygdalar primary cell cultures. The authors conclude that ketamine and isoflurane induce pronounced long-lasting anxiety-related behaviors in male rats.